Cannabis for Crohn's and IBS: What Gastroenterology Research Actually Shows

Gastrointestinal conditions are among the most common reasons patients seek medical cannabis. Survey data from multiple state programs shows that Crohn’s disease, ulcerative colitis, and irritable bowel syndrome consistently rank in the top ten qualifying conditions. Patient reports of symptom relief are overwhelmingly positive. But the clinical trial data tells a more complex story — one where subjective improvement sometimes diverges from objective measures of disease activity.

Understanding this divergence is essential for patients, physicians, and anyone trying to evaluate whether cannabis has genuine therapeutic value for GI conditions.

The Endocannabinoid System in the Gut

The gastrointestinal tract is one of the most cannabinoid-receptor-dense organ systems in the body. Both CB1 and CB2 receptors are expressed throughout the GI tract, and the endocannabinoid system (ECS) plays documented roles in nearly every major GI function:

The density of cannabinoid signaling in the gut explains why GI effects — appetite changes, nausea relief, altered bowel habits — are among the most commonly reported effects of cannabis use. It also provides a clear biological rationale for investigating cannabinoids as treatments for GI diseases.

Crohn’s Disease: The Evidence

Crohn’s disease is a chronic inflammatory bowel disease (IBD) that can affect any part of the GI tract, producing symptoms including abdominal pain, diarrhea, weight loss, and fatigue. It affects approximately 500,000 Americans. Current treatments include immunosuppressants, biologics (anti-TNF agents, anti-integrins), and corticosteroids — all of which carry significant side effects and fail to achieve remission in a substantial proportion of patients.

The Naftali Studies (Israel)

The most cited controlled trials of cannabis for Crohn’s disease come from Timna Naftali and colleagues at Meir Medical Center in Israel.

Naftali et al. (2013), Clinical Gastroenterology and Hepatology. The first randomized, placebo-controlled trial of cannabis for Crohn’s disease. Twenty-one patients with moderate to severe Crohn’s disease (CDAI score >200) who had not responded to standard treatments were randomized to smoke cannabis cigarettes containing 115 mg THC twice daily or placebo cigarettes for 8 weeks.

Results: 5 of 11 patients (45%) in the cannabis group achieved clinical remission (CDAI <150) compared to 1 of 10 (10%) in the placebo group. Ten of 11 cannabis patients (90%) had a clinical response (CDAI reduction >100 points) compared to 4 of 10 placebo patients (40%). Cannabis patients also reported significant improvements in appetite, sleep, and quality of life.

However — and this is the critical caveat — objective markers of intestinal inflammation (CRP, endoscopic scores) did not improve significantly. Patients felt better without demonstrating reduced mucosal inflammation.

Naftali et al. (2017), Inflammatory Bowel Diseases. A follow-up trial testing CBD-only treatment (10 mg CBD, sublingually, twice daily) in 19 Crohn’s disease patients. This study was negative — CBD at this dose showed no significant benefit over placebo on any outcome measure. The dose was low by current standards, and the route of administration (sublingual CBD) may have been insufficient.

Naftali et al. (2021), Gastroenterology. The most rigorous trial to date. Thirty-two Crohn’s patients with moderate disease were randomized to cannabis oil (CBD:THC ratio of approximately 4:1, with a maximum THC dose of 50 mg/day) or placebo oil for 8 weeks. The cannabis group showed significant improvement in quality of life scores and the Crohn’s Disease Activity Index (CDAI). Once again, however, the primary outcome — endoscopic improvement (assessed by the Simple Endoscopic Score for Crohn’s Disease, SES-CD) — did not reach statistical significance, though there was a trend toward improvement.

Summary of Crohn’s Disease Trials

The pattern is consistent: cannabis improves how Crohn’s patients feel (symptoms, quality of life, pain, appetite) without clearly reducing the underlying intestinal inflammation that drives disease progression. This distinction is medically important — symptom relief is valuable, but if mucosal inflammation persists, the risk of complications (strictures, fistulas, surgery) may continue.

Ulcerative Colitis: Limited but Growing Data

Ulcerative colitis (UC) is the other major form of IBD, characterized by continuous inflammation of the colonic mucosa. Approximately 900,000 Americans have UC. The cannabis evidence for UC is thinner than for Crohn’s disease but follows a similar pattern.

Irving et al. (2018), Clinical Gastroenterology and Hepatology. A randomized, double-blind, placebo-controlled trial of a CBD-rich botanical extract (containing up to 4.7% THC) in 60 UC patients. After 10 weeks, there was no significant difference in remission rates between the cannabis and placebo groups on the primary outcome. However, secondary outcomes showed improvements in quality of life and physician global assessment scores. Side effects were common in the cannabis group, particularly dizziness and somnolence, suggesting the dosing may not have been optimal.

Observational data. A 2019 retrospective study by Mbachi et al. using the National Inpatient Sample database found that among hospitalized UC patients, cannabis users had lower rates of colectomy (OR: 0.68), lower in-hospital mortality (OR: 0.69), and shorter hospital stays compared to non-users. This is intriguing but is observational and subject to significant confounding — cannabis-using UC patients may differ systematically from non-users in ways that affect outcomes independent of cannabis.

Irritable Bowel Syndrome: Targeting Visceral Hypersensitivity

IBS differs fundamentally from IBD. It is a functional GI disorder — meaning there is no visible inflammation or structural damage — characterized by altered bowel habits (diarrhea, constipation, or alternating), abdominal pain, and bloating. It affects an estimated 25–45 million Americans.

The theoretical rationale for cannabis in IBS is strong: the endocannabinoid system modulates visceral pain, GI motility, and the gut-brain axis — all of which are dysfunctional in IBS. Visceral hypersensitivity (an exaggerated pain response to normal gut activity) is considered a hallmark of IBS, and CB1 receptor activation in the gut reduces visceral nociception.

Esfandyari et al. (2007), Gut. A randomized, double-blind, placebo-controlled study of dronabinol (synthetic THC, 2.5 mg or 5 mg) in 75 healthy volunteers and IBS-D (diarrhea-predominant IBS) patients. Dronabinol significantly reduced colonic motility (transit time) and increased colonic compliance (stretchiness) compared to placebo. The effect was more pronounced in IBS-D patients than in healthy volunteers, suggesting a specific therapeutic effect in the disease state.

Wong et al. (2011), Clinical Gastroenterology and Hepatology. A randomized, double-blind, placebo-controlled trial of dronabinol (5 mg twice daily) in 36 IBS-D patients. Dronabinol reduced gut motility and improved the fasting motility index but did not significantly affect pain scores at this dose.

Observational data. Large surveys consistently show that IBS patients who use cannabis report significant symptom improvement, particularly in pain and diarrhea. A 2020 survey in Cannabis and Cannabinoid Research found that 83% of IBS patients using cannabis reported improvement in abdominal pain and 76% reported improvement in bowel frequency.

The Endocannabinoid Deficiency Connection

IBS has been specifically proposed as a condition potentially caused by endocannabinoid deficiency (CED). This hypothesis, first articulated by neurologist Ethan Russo, suggests that IBS, migraine, and fibromyalgia may share a common underlying pathophysiology of reduced endocannabinoid tone.

Supporting evidence includes:

• Polymorphisms in the CNR1 gene (encoding CB1 receptors) have been associated with IBS susceptibility in some population studies
• IBS patients show altered expression of FAAH and NAPE-PLD (enzymes involved in endocannabinoid synthesis and degradation) in intestinal biopsies
• The symptom profile of IBS (visceral pain, altered motility, stress sensitivity) maps closely onto the known functions of the gut endocannabinoid system

If the CED hypothesis is correct, cannabinoid supplementation could address the root cause of IBS symptoms rather than merely masking them. However, this remains a hypothesis — elegant and plausible but not yet confirmed by definitive clinical data.

Mechanism: Why Symptoms Improve Without Inflammation Resolution

The observation that cannabis improves GI symptoms without clearly reducing inflammation (in IBD) is not paradoxical when you understand the multiple mechanisms at work:

Visceral analgesia. CB1 activation reduces visceral pain signaling through both peripheral (gut-level) and central (spinal cord, brainstem) mechanisms. This can reduce pain perception without affecting the source of inflammation.

Reduced motility. THC slows GI transit through CB1 activation on enteric neurons. For patients with diarrhea-predominant symptoms (common in both Crohn’s and IBS-D), this effect reduces stool frequency and urgency.

Anti-emetic effect. THC is a well-established anti-emetic, acting on CB1 receptors in the brainstem vomiting center. Nausea is a common symptom in both IBD and IBS.

Appetite stimulation. Weight loss and reduced appetite are hallmarks of active Crohn’s disease. THC’s appetite-stimulating properties directly address this symptom.

Stress and anxiety reduction. The gut-brain axis means that anxiety directly worsens GI symptoms. Cannabis reduces anxiety (at appropriate doses) and may improve GI symptoms partly through this central mechanism.

Potential anti-inflammatory effects. CB2 receptor activation on gut immune cells does reduce pro-inflammatory cytokine production in laboratory models. The question is whether the doses and formulations used in clinical trials have been sufficient to produce clinically meaningful anti-inflammatory effects in the gut mucosa. Higher doses, different cannabinoid ratios, or longer treatment periods may be needed.

Practical Guidance for GI Patients

For IBD patients (Crohn’s and UC):

• Cannabis may meaningfully improve quality of life, pain, appetite, and sleep — but it should not replace evidence-based disease-modifying therapy (biologics, immunosuppressants)
• Do not discontinue prescribed medications based on symptom improvement from cannabis — ongoing inflammation can cause irreversible damage even when symptoms are controlled
• Work with a gastroenterologist who is open to discussing cannabis as an adjunctive (add-on) therapy
• Products containing both THC and CBD appear more effective than CBD alone based on the available trial data
• Monitor objective inflammation markers (CRP, fecal calprotectin) alongside symptom assessment

For IBS patients:

• The theoretical rationale for cannabis in IBS is strong, particularly for diarrhea-predominant subtype
• Low-dose THC (2.5–5 mg) may be sufficient for motility effects; high doses may cause paradoxical GI disturbance
• CBD alone has limited evidence for IBS symptom relief
• Consider cannabis as one tool among several (low-FODMAP diet, stress management, fiber supplementation, peppermint oil)

For all GI patients using cannabis:

• Start with low doses and titrate slowly
• Inhaled cannabis provides faster relief for acute symptom episodes; oral forms provide more sustained effect for chronic management
• Be aware that chronic, heavy cannabis use carries its own GI risk: cannabinoid hyperemesis syndrome (CHS), a paradoxical condition characterized by severe, cyclical vomiting in long-term heavy users
• Keep a symptom diary that tracks both cannabis use and GI symptoms to objectively assess whether cannabis is helping

The State of the Evidence

The cannabis-GI evidence base is stronger than for many conditions cannabis is used for, but it has significant gaps. The Naftali trials provide genuine controlled data for Crohn’s disease. The IBS data is mechanistically compelling but clinically preliminary. The UC data is early and underpowered.

What the field needs is larger, longer, more rigorously designed trials using standardized cannabinoid preparations at adequate doses, with both subjective (symptom) and objective (endoscopic, histological) endpoints. The consistent finding that symptoms improve more than inflammation markers suggests either that current formulations are not anti-inflammatory enough in the gut, or that the symptomatic benefits (pain relief, reduced motility, appetite) are the primary therapeutic mechanisms. Clarifying this distinction has important implications for how cannabis should be positioned in GI treatment — as symptom management or as disease modification.

For now, cannabis occupies a reasonable place in the GI treatment toolkit: not as a replacement for standard therapy, but as a potentially valuable adjunct for symptoms that standard therapy often fails to adequately control. That is not a revolutionary claim. It is an honest one, grounded in the data we have.